Work UpdateWorkplace, employment and industry news

Press Release · Hone Health

Hone Health Raises $228M to Expand Physician-Led Longevity Care for Men and Women

Distributed by Work Update · Originally issued via PR Newswire

The funding, led by MarcyPen Capital Partners, will fuel new clinical pathways and the AI-enabled technology that turns patient data into proactive physician-directed care

NEW YORK, Nov. 18, 2026 — Hone Health, a physician-led longevity platform that helps people design a personalized plan for their health and longevity, today announced it has raised $228M in financing. The round was led by MarcyPen Capital Partners, a first-of-its-kind global investment platform that provides strategic capital to growth stage consumer businesses that create, move, and lead culture. MarcyPen has been a partner to Hone for over two years, having led the company's Series A financing, a role that had not previously been disclosed, and continuing to support the company through follow-on investments.

Hone Health

The Series A extension included additional participation from Pentland Ventures, Kinship Ventures co-founded by Gwyneth Paltrow and Moj Mohdara, Hanwha, Gannet Capital, humbition, and Comma Capital, and ID Ventures. The investment is structured as $28M in equity as a Series A financing and $200M in growth financing from General Catalyst's Customer Value Fund (CVF).

David Grutman has joined Hone Health as a strategic investor and advisor. Grutman has also brought a group of high-profile strategic investors, including Marcello Hernández, Nick Jonas, Joe Jonas, Kevin Jonas, Braxton Berrios, and Kelly Rowland, Jason Strauss and Noah Tepperberg. Additional investors include former NBA player Josh Childress, along with Quentin Dolan, Raj Gokal, Tushar Jain, Kyle Samani, Halle Tecco, and Zachary Gordan. The financing brings Hone's total equity funding to $65 million. After years of reactionary purchasing, consumers have shifted their focus to proactive wellness. 89% of women want to be more proactive in managing their health, and in 2025, nutrition and personal care spending accounted for over 90% of consumer health sales, reflecting a more proactive approach to well-being.

"Today, consumers have almost limitless options when it comes to preventative health, but what people are looking for is the highest level of insight into their metrics, so that they can make more informed decisions about their health," said Saad Alam, Co-Founder & CEO of Hone Health. "Hone combines comprehensive diagnostic testing, physician-led care, and AI-powered insights to deliver that level of understanding. This funding will allow us to extend that vision across new therapeutic categories and start building toward our ultimate vision: a research platform to accelerate health outcomes."

Jay Brown, Co-Founder and Managing Partner at MarcyPen Capital Partners, said, "Saad and the team at Hone are proven business builders dedicated to making it easier for people to live better, healthier lives. We believe in their vision and are proud to deepen our partnership with them."

Expanding the Infrastructure for Personalized Healthspan Medicine

Hone will use the investment to support five areas of expansion:

  • Broader Clinical Care: Launch and scale physician-led programs across metabolic health, PMOS, inflammation, and immunity, giving patients a more connected view of the factors influencing their health.
  • Advanced Diagnostics: Integrate additional diagnostic tools into longitudinal patient care, including full-body MRI, DEXA scans, coronary CT angiography, and gut microbiome analysis, while creating one of the most complete health datasets ever assembled.
  • Clinical Technology: Advance AI-enabled care and the tools that bring together lab results, health history, symptoms, medications, and longitudinal outcomes to help physicians personalize and adapt care – accelerating the buildout of the technology that turns biomarkers into personalized treatment plans.
  • Emerging Therapies: Launch a physician-supervised peptide program providing eligible patients with access to select peptide therapies where legally available and clinically appropriate.
  • Research & Trials: Accelerate the clinical trials infrastructure that allows Hone to understand what kinds of care are driving the best patient outcomes.

Introducing Hone Black

Finally, Hone will publicly launch Hone Black, its most comprehensive and personalized membership. The concierge longevity program has operated in stealth for the past year, serving a select group of high-profile patients.

Hone Black combines extensive diagnostics (1,600+ health markers) with ongoing medical care from a dedicated team of physicians responsible for whole-body care. Treatment options span prescription medications, supplements, peptides, and lifestyle guidance, as well as exosome and stem cell therapies.

"When I started goop, wellness was a niche conversation," said Gwyneth Paltrow, founder and CEO of goop and co-founder of Kinship Ventures. "Today it's one of the biggest categories in the world, and the next step is bringing real health and wellness to the masses, not just the few. Saad has built Hone to do exactly that, with serious science and at real scale. That's why Kinship invested, and we could not be more excited about what's ahead."

"The next great health company will be built on data," said Moj Mahdara, co-founder and managing partner of Kinship Ventures. "Hone has treated more than 200,000 patients and turned that into one of the largest hormone and metabolic datasets in the world, making its physicians smarter with every patient. Kinship is proud to stand alongside Saad as Hone scales."

"People have never had more data about their own bodies and never less guidance on what to do with it," said Omar Hatteea, Investment Manager at Pentland Ventures. "Hone closes that gap by pairing serious diagnostics with physicians who stay with a patient over years rather than appointments. That longitudinal relationship is the cornerstone of our Health OS thesis, and we are excited for what lies ahead for Hone."

The financing follows Hone's $33 million Series A, announced in January 2025, which supported the company's expansion beyond hormone health optimization into broader longevity care. Since that round, Hone has launched a cardiovascular program that evaluates risk using advanced health markers and integrated Prenuvo whole-body MRI and BodySpec DEXA scans.

SOURCE Hone Health

About Hone Health

Hone Health is a physician-led longevity platform that helps people who want more control over how they age, design a personalized plan for their health. Hone combines comprehensive biomarker testing, one-on-one physician consultations, and personalized treatment into an ongoing relationship that adapts as patients' goals change. Treatment spans testosterone replacement therapy, menopause hormone therapy, weight management, peptides, thyroid, heart health, and sexual health. Care is powered by Hone's proprietary AI clinical platform, Longevity OS, which gives physicians a real-time view of each patient's health across specialties. With more than 200,000 patients treated, 750,000 tests administered, and 25 million health markers processed Hone has built one of the world's largest repositories of hormone and metabolic data. That data feeds Longevity OS, sharpening its clinical intelligence with every patient Hone treats. For more information, visit www.honehealth.com | @hone.health

About MarcyPen Capital Partners

MarcyPen Capital Partners ("MarcyPen") is a first-of-its-kind global investment platform that provides strategic capital to growth-stage consumer businesses that create, move, and lead culture. Founded by builders of some of the most iconic brands of our time, the firm provides solutions-oriented capital to leading consumer businesses positioned to meet the needs and expectations of the everchanging consumer, prioritizing strong engagement and collaboration with the companies it invests in. MarcyPen's trusted formula combines a business-building playbook with a highly influential global ecosystem of partners, operators, and leaders. The firm pursues investments globally across subsectors that include beauty & personal care, consumer products, fashion & lifestyle, food & beverage, health & wellness, marketplaces, PR & creative, and tech-enabled services.

About Kinship Ventures

Kinship Ventures is a multi-stage venture investment platform founded by Gwyneth Paltrow and Moj Mahdara, backing high-agency founders who invent new markets and build enduring companies that define the next era. Kinship invests from early conviction through scale across frontier technology, AI, health, longevity, women's health, and next-generation consumer. Built by founders and operators, Kinship brings more than capital — combining hands-on operating experience with strategic access, distribution, cultural intelligence, and a deeply connected ecosystem to help founders anticipate what's next, navigate pivotal moments, and build for the long term. Learn more at kinshipventures.co.